Gadeholt, O. http://orcid.org/0000-0001-6320-4818
Feuchtenberger, M. http://orcid.org/0000-0001-8028-8099
Wech, T. http://orcid.org/0000-0002-2813-7100
Schwaneck, E. C. http://orcid.org/0000-0003-1935-2092
Article History
Received: 12 November 2018
Accepted: 14 February 2019
First Online: 26 February 2019
Compliance with ethical standards
:
: OG: speaker’s fees from Abbvie, Chugai, Janssen-Cilag, Novartis, and Sanofi. Grants from Abbvie, Chugai, Janssen-Cilag, Lilly, Novartis and Roche. Advisory board participation for Novartis. All outside the submitted work. MF: personal Fees from Abbvie, Chugai, Janssen-Cilag MSD, Pfizer, Roche and UCB. All outside the submitted work. TW: research grant from Siemens Healthcare. Outside the submitted work. ECS: speaker’s fees from Abbvie, Chugai, Jansen-Cilag, Lilly, Novartis and Shire. Grants from Abbvie, Celgene, Chugai, Novartis and Shire. All outside the submitted work.
: Final approval by the ethics committee of the University of Würzburg, Würzburg, Germany 20.07.2018 (Protocol Number 22/18). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: No application was submitted to the ethics commission of the University of Würzburg for permission to share the obtained data. Hence, the data cannot be made available for further analysis.